Next Oncology is occupying space in the Texas Medical Center to conduct cancer-fighting clinical trials in Houston.

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Texas Children's Hospital and The University of Texas MD Anderson Cancer Center have announced a collaboration dedicated to ...

In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph ...

Aprea Therapeutics has dosed a subject with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) ...

Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...

While overall rates of colorectal cancer have been declining in the United States, the numbers have been steadily increasing ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

Since joining, he has served as chair of surgical oncology, vice president of medical and academic affairs for MD Anderson’s Cancer Network, vice president for clinical operations strategy ...

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, Fellow of the AACR Academy, as the AACR President-Elect for 2025-2026. Flaherty will become ...

These two general immune response findings, immune response at baseline and increasing immune response over time, were also observed in the Phase IIb clinical trial for HLA-A*02 only patients. These ...